Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are generally
thought to have high mortality rates. However, many cases can be treated with the right …

Tuberculosis (TB) remains a major public health problem, representing the second leading
cause of death from infectious diseases globally, despite being nearly 100% curable …

Background Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new
antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro …

N ɛ-Acetylation of lysine residues represents a pivotal post-translational modification used
by both eukaryotes and prokaryotes to modulate diverse biological processes …

Background In Africa, fewer than half of patients receiving therapy for multidrug-resistant TB
(MDR TB) are successfully treated, with poor outcomes reported for HIV-coinfected patients …

Multidrug-resistant tuberculosis (MDR-TB) threatens global TB control. The lengthy
treatment includes one of the injectable drugs kanamycin, amikacin, and capreomycin …

Background Treatment-related outcomes in patients with extensively drug-resistant
tuberculosis (XDR-TB) are poor. However, data about the type, frequency and severity of …

Tuberculosis (TB) is an intracellular infectious disease caused by the airborne bacterium,
Mycobacterium tuberculosis. Despite considerable research efforts, the treatment of TB …

Background Multidrug-resistant tuberculosis (MDR-TB) is an increasing challenge to health
services globally. Although new drugs are in development, current guidelines still …

Multidrug‐resistant tuberculosis (MDR‐TB), caused by Mycobacterium tuberculosis strains
resistant to at least isoniazid (INH) and rifampin (1), is difficult to treat effectively and requires …